Journal ArticleOPEN ACCESS

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia

Blood (2026)
DOI: 10.1182/blood.2026033569
3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

FLT3-internal tandem duplication measurable residual disease testing for patients in remission from acute myeloid leukemia is now recommended by the recently updated clinical standard-of-care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.

Cite

CITATION STYLE

APA

Hourigan, C. S., Beugelink, L., Othman, J., Gui, G., Ivey, A., Dillon, R., … Valk, P. J. M. (2026). ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia. Blood. https://doi.org/10.1182/blood.2026033569

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free